Benign Prostatic Hyperplasia Therapeutics Market Size Poised to Reach USD 9.39 Billion, Globally, by 2030, Driven by Impressive 5.0% CAGR: AMR

Allied Market Research published a report, titled, "Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class (Alpha Blocker, 5-Alpha Reductase Inhibitor, Phosphodiesterase-5 Inhibitor, and Others) and Therapy Type (Mono Drug Therapy and Combination Drug Therapy): Global Opportunity Analysis and Industry Forecast, 2021-2030." According to the report, the global Benign Prostatic Hyperplasia Therapeutics Market Size was Valued at USD 5.69 billion in 2020 and is Projected to Garner USD 9.39 billion by 2030, registering a CAGR of 5.0% from 2021 to 2030.

The report provides a detailed analysis of the top investment pockets, top winning strategies, drivers & opportunities, market size & estimations, competitive landscape, and evolving market trends. The market study is a helpful source of information for the frontrunners, new entrants, investors, and shareholders in crafting strategies for the future and heightening their position in the market.

Download Sample PDF Report with Graphs and Figures Here: https://www.alliedmarketresearch.com/request-sample/4708

What are the factors driving the Benign Prostatic Hyperplasia Therapeutics Market?

Increase in prevalence of benign prostatic hyperplasia, rise in awareness toward urological disorders, and surge in healthcare expenditure worldwide drive the growth of the global benign prostatic hyperplasia therapeutics market. However, preference for minimally invasive surgical therapies restrains the market growth. On the other hand, huge number of products in the pipeline and opportunities in untapped geographies create new opportunities in the coming years.

Top Benign Prostatic Hyperplasia Therapeutics Companies

• Abbott Laboratories
• AbbVie (Allergan Plc)
• Astellas Pharma Inc.
• Boehringer Ingelheim Pharma GmbH & Co. KG
• Eli Lilly and Company
• GlaxoSmithKline plc.
• Merck & Co., Inc. (Merck Sharp & Dohme Corp)
• Pfizer Inc.
• Sanofi
• Teva Pharmaceutical Industries Limited

Benign Prostatic Hyperplasia Therapeutics Market Segmentation: -

Based on therapeutic class, the alpha blockers segment contributed to the largest share in 2020, holding nearly three-fifths of the global benign prostatic hyperplasia therapeutics market, and is projected to maintain its lead position during the forecast period. This is due to rise in availability of various branded as well as generic drugs for treatment. However, the 5-alpha reductase inhibitors segment is estimated to manifest the highest CAGR of 6.5% from 2021 to 2030, owing to rapid suppression of dihydrotestosterone (DHT) that affects tissue growth in the prostate.

Based on therapy, the mono drug therapy segment accounted for the highest share in 2020, contributing to more than three-fourths of the global benign prostatic hyperplasia therapeutics market, and is estimated to maintain its lead in terms of revenue during the forecast period. This is attributed to increase in the number of BPH cases globally and availability of various mono drugs. However, the combination drug therapy segment is expected to witness the largest CAGR of 6.2% from 2021 to 2030. This is due to approval of combination therapy and various under-trial studies.

Based on region, North America held the largest market share in 2020, accounting for more than two-fifths of the global benign prostatic hyperplasia therapeutics market, and is expected to maintain its dominance by 2030. This is due to increase in benign prostatic hyperplasia cases, robust R&D infrastructure for life science research, surge in adoption of advanced technologies, improved therapeutics, and presence of key players. However, Asia-Pacific is estimated to witness the fastest CAGR of 6.8% from 2021 to 2030, owing to continuous government support for R&D activities for pharmaceutical and biotechnology, increase in public-private investments, and rise in the number of initiatives for urological disorder awareness.

Purchase the Report: https://www.alliedmarketresearch.com/purchase-enquiry/4708

Our Market Research Solution Provides You Answer to Below Mentioned Question:

Which are the driving factors responsible for the growth of market?
Which are the roadblock factors of this market?
What are the new opportunities, by which market will grow in coming years?
What are the trends of this market?
Which are main factors responsible for new product launch?
How big is the global & regional market in terms of revenue, sales and production?
How far will the market grow in forecast period in terms of revenue, sales and production?
Which region is dominating the global market and what are the market shares of each region in the overall market in 2022?
How will each segment grow over the forecast period and how much revenue will these segments account for in 2030?
Which region has more opportunities?

By Region Outlook

North America
(U.S., Canada, Mexico)
Europe
(Germany, France, UK, Italy, Spain, Rest of Europe)
Asia-Pacific
(Japan, China, India, Rest of Asia-Pacific)
LAMEA
(Brazil, Saudi Arabia, South Africa, Rest of LAMEA)

Contact Details:

David Correa
USA/Canada (Toll-Free): +1-800-792-5285, +1-503-894-6022
help@alliedmarketresearch.com

About Us

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.

This release was published on openPR.